Mounjaro

News

Eli Lilly has posted another record quarter of revenue growth, up 48% to $23bn, with Mounjaro and Zepbound now making up two-thirds of the total.

News

The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.

News

Eli Lilly's LillyDirect, an important driver of sales of its weight-loss drugs in the US, has now arrived in the UK – with modifications.

News

France's Health Minister has said that the country is the first in the EU to provide reimbursement coverage for GLP-1 weight-loss therapies.

News

Investors are itching for news on the rollout of Lilly's oral weight-loss drug Foundayo, but there's little information in its first-quarter update.

News

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.